Medicine

The European respiratory journal

international journal of clinical oncology

experimental and therapeutic medicine

polski merkuriusz lekarski : organ polskiego towarzystwa lekarskiego

[1] Diagnostic challenges in interstitial lung diseases using the example of microscopic usual interstitial pneumonia image in a patient with the clinical hypothesis of idiopathic pulmonary fibrosis - a case report.

[2] Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.

[3] Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.

[4] Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey.

[5] Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B

[6] Detection of microRNA expression levels based on microarray analysis for classification of idiopathic pulmonary fibrosis.

[7] anti-cytokine therapy in fibrosing alveolitis: where are we now?

[8] mesenchymal stem cells for the treatment of idiopathic pulmonary fibrosis

[9] interstitial lung diseases in saudi arabia: a single-center study

[10] genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment

[11] skewed lung ccr4 to ccr6 cd4+ t cell ratio in idiopathic pulmonary fibrosis is associated with pulmonary function

[12] june 2014 phoenix pulmonary journal club: new therapies for ipf and ebus for sardoidosis

[13] approach to acute exacerbation of idiopathic pulmonary fibrosis

[14] Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.

[15] Diagnostic challenges in interstitial lung diseases using the example of microscopic usual interstitial pneumonia image in a patient with the clinical hypothesis of idiopathic pulmonary fibrosis - a case report.

[16] Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.

[17] Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis

[18] Is probable usual interstitial pneumonia pattern synonymous with idiopathic pulmonary fibrosis?

[19] Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis

[20] Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: Risk factors and outcome

[21] Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management

[22] Idiopathic Pulmonary Fibrosis—Clinical presentation, outcome and baseline prognostic factors in a Portuguese cohort

[23] The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias

[24] Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study

[25] Dysregulated balance of lung macrophage populations in idiopathic pulmonary fibrosis revealed by single-cell RNA seq: an unstable "ménage-à-trois".

[26] Prediction of progression in idiopathic pulmonary fibrosis using CT scans at baseline: A quantum particle swarm optimization - Random forest approach.

[27] Recapitulating idiopathic pulmonary fibrosis related alveolar epithelial dysfunction in a human iPSC-derived air-liquid interface model.

[28] Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.

[29] Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B

[30] Detection of microRNA expression levels based on microarray analysis for classification of idiopathic pulmonary fibrosis.

[31] Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

[32] a dataset of 26 candidate gene and proinflammatory cytokine variants for association studies in idiopathic pulmonary fibrosis (ipf): frequency distribution in normal czech population

[33] activation of oncogenic pathways in idiopathic pulmonary fibrosis

[34] mesenchymal stem cells for the treatment of idiopathic pulmonary fibrosis

[35] anca-negative idiopathic pulmonary fibrosis developed into anca-positive rapidly progressive glomerulonephritis after 12 years follow up

[36] genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment

[37] adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey

[38] mmrc dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis

[39] skewed lung ccr4 to ccr6 cd4+ t cell ratio in idiopathic pulmonary fibrosis is associated with pulmonary function

[40] analysis of microarray-identified genes and micrornas associated with idiopathic pulmonary fibrosis

[41] approach to acute exacerbation of idiopathic pulmonary fibrosis